Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Roche's ENSPRYNG Reduces MOGAD Relapse Risk by 68% in Phase III

Roche announced positive Phase III METEOROID study results for ENSPRYNG (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The study met its primary endpoint, demonstrating a 68% reduction in the risk of a new relapse compared to placebo. At 48 weeks, 87% of patients on ENSPRYNG were relapse-free, versus 67% on placebo. Key secondary endpoints, including a 66% reduction in the annualised relapse rate, were also met. The safety profile was consistent with previous data, with no new signals reported. These data will be submitted to regulatory authorities, positioning ENSPRYNG as a potential first approved treatment for MOGAD.

• The Phase III METEOROID study successfully met its primary endpoint, showing that ENSPRYNG (satralizumab) significantly reduced the risk of a new MOGAD relapse by 68% compared to placebo (p=0.0025). This translates to 87% of ENSPRYNG-treated patients remaining relapse-free at 48 weeks, a substantial improvement over the 67% observed in the placebo group, with response onset as early as 8 weeks.
• ENSPRYNG also demonstrated significant improvements across several key secondary endpoints. It reduced the annualised relapse rate (ARR) by 66% (p=0.0030), indicating fewer acute relapses. Furthermore, the drug led to a 79% reduction in the annualised rate of active lesions on MRI across the CNS and a 73% lower proportion of patients requiring rescue therapies like steroids, plasma exchange, or intravenous immunoglobulins (p=0.0024).
• The safety profile of ENSPRYNG in the METEOROID study was consistent with its established data from over a decade of clinical trial and post-approval experience in NMOSD, with no new safety signals identified. Common adverse events (≥5% and more frequent than placebo) included injection-related reactions, influenza, arthralgia, back pain, sinusitis, and diarrhoea, with low rates of treatment interruption and no treatment-related serious adverse events or fatalities.

Addressing the Critical Unmet Need in MOGAD Treatment

MOGAD presents significant therapeutic challenges due to the absence of FDA-approved treatments and limited understanding of optimal management strategies. Current treatment approaches are hampered by insufficient evidence from controlled studies and variable patient responses to available immunotherapies.

• Absence of approved therapies - No FDA-approved treatments exist for MOGAD relapse prevention, leaving clinicians to rely on off-label immunotherapies without clear regulatory guidance

• Limited treatment efficacy data - Most evidence comes from retrospective studies rather than prospective randomized controlled trials, making it difficult to validate treatment efficacy and establish evidence-based guidelines

• Inconsistent immunotherapy effectiveness - Rituximab shows less robust effectiveness in MOGAD compared to AQP4-IgG+NMOSD, with breakthrough relapses occurring in 18.5% of patients on chronic immunotherapy

• Lack of consensus on maintenance therapy - No agreement exists on whether maintenance treatment should be initiated for patients with single clinical events or optimal treatment duration

• Variable relapse rates across therapies - Despite treatment with disease-modifying drugs including rituximab, mycophenolate mofetil, and azathioprine, relapse rates remain substantial with unclear comparative effectiveness

• Ineffectiveness of MS treatments - Traditional multiple sclerosis disease-modifying agents appear ineffective, with all patients experiencing breakthrough relapses (ARR 1.5)

• Incomplete pathophysiologic understanding - The exact pathologic mechanisms and extent of MOG-IgG antibody pathogenicity remain poorly understood, limiting rational drug development

• Diagnostic complexity - Substantial clinical and radiological overlap with other demyelinating conditions and neoplasms frequently leads to misdiagnosis and delayed appropriate treatment

• Suboptimal recovery outcomes - Only 38% of patients fully recover at 4 weeks post-steroid treatment, with 69% showing residual deficits at follow-up, including moderate to severe impairment in 17% of adults

• Need for biomarker development - Limited availability of predictive biomarkers hampers ability to forecast disease course and guide personalized treatment decisions

METEOROID: Unpacking ENSPRYNG's Pivotal Phase III Results

The current landscape of MOGAD research is characterized by predominantly retrospective observational studies, as prospective treatment trials are still needed to determine optimal therapeutic approaches. Most clinical evidence has emerged from multicenter cohort studies and registry analyses, with treatment plans remaining individualized based on clinical manifestations and disease severity.

ENSPRYNG's IL-6 Inhibition: Beyond MOGAD in CNS Autoimmunity

Beyond its established role in NMOSD, satralizumab is expanding into autoimmune encephalitis (AIE), representing a significant advancement in CNS autoimmunity treatment. The CIELO study marks the first Phase 3 investigation of satralizumab in AIE, targeting patients with NMDAR-IgG+ or LGI1-IgG+ subtypes where no approved therapies currently exist.

The CIELO trial employs a two-part design: Part 1 consists of a 52-week primary treatment period with subcutaneous satralizumab or placebo administered at Weeks 0, 2, 4, and every 4 weeks thereafter. Part 2 offers an optional extension where participants may continue randomized treatment, transition to open-label satralizumab, or discontinue study drug while maintaining follow-up assessments.

ENSPRYNG's Safety Profile and Future Regulatory Path

Clinical trials and observational studies for MOGAD treatments have documented varying safety profiles across different therapeutic interventions. The most comprehensive safety data comes from rituximab studies, while emerging evidence suggests tocilizumab may offer a favorable safety profile. Treatment discontinuation rates due to adverse events vary significantly by medication class.

• Rituximab demonstrates the lowest discontinuation rate at 1.52% (3/197 patients), with reported adverse events including infusion reactions and severe infections in approximately 12% of patients across mixed cohorts, though long-term follow-up studies show no adverse events with proper monitoring protocols

• Azathioprine shows the highest discontinuation rate due to adverse effects at 10.81% (4/37 patients), with one documented case of myelitis development following COVID-19 vaccination in a patient on azathioprine maintenance therapy

• Mycophenolate mofetil exhibits moderate tolerability with a 7.69% discontinuation rate (3/39 patients) due to adverse effects, though one study of 30 patients reported no discontinuations due to intolerable side effects

• Tocilizumab demonstrates a generally favorable safety profile with no severe or unexpected safety signals observed in long-term studies, though infection rate increases occurred in 2 of 7 patients in one cohort, and one patient developed dyslipidemia

• Ofatumumab presents higher infusion reaction rates compared to other anti-CD20 monoclonal antibodies, with 86% experiencing reactions during first infusion decreasing to 42% by last infusion, plus six patients requiring hospitalization for infections

• IVIG therapy shows a 12% overall discontinuation rate with only 2% (2/59 patients) stopping due to adverse effects specifically, while 88% of patients continued maintenance therapy at final follow-up

• COVID-19 vaccination appears well-tolerated in MOGAD patients, with only 7% (3/43) experiencing clinical relapse post-vaccination and no serious adverse events directly attributed to vaccination

ENSPRYNG's MOGAD Breakthrough: Reshaping the Neuroinflammatory Landscape

The recent positive Phase III METEOROID study results for Roche's ENSPRYNG (satralizumab) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) mark a pivotal moment for patients suffering from this severe, rare neuroinflammatory disorder. MOGAD, increasingly recognized as a distinct entity from aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) and multiple sclerosis, has historically lacked any approved targeted treatments. Patients have largely relied on broad immunosuppressants, corticosteroids, or intravenous immunoglobulin (IVIg), often with limited evidence from observational studies. The prospect of ENSPRYNG becoming the first approved therapy for MOGAD relapse prevention addresses a critical unmet need, offering a specific, evidence-based option that could significantly improve patient outcomes and reduce the cumulative neurological damage associated with recurrent attacks.

This development not only offers hope for MOGAD patients but also carries significant strategic implications for Roche and the broader neuroinflammatory landscape. ENSPRYNG, an interleukin-6 receptor (IL-6R) antagonist, is already approved for AQP4-IgG+ NMOSD. Its success in MOGAD further validates the IL-6 pathway as a key therapeutic target across these distinct but related autoimmune demyelinating conditions. This expanded utility reinforces the drug's scientific foundation and could encourage further exploration of IL-6 inhibition in other autoimmune diseases, such as Thyroid Eye Disease, where satralizumab is also under investigation. For Roche, this means securing a first-mover advantage in a new market segment, differentiating ENSPRYNG from other approved NMOSD therapies like C5 inhibitors (eculizumab, ravulizumab) and B-cell depleters (inebilizumab) that do not currently hold a MOGAD indication. This strengthens Roche's position in rare neuroinflammatory diseases and could influence diagnostic and treatment algorithms, potentially simplifying management for clinicians facing diagnostic ambiguities between MOGAD and AQP4-IgG+ NMOSD.

However, this promising outlook comes with important considerations. While the METEOROID study reported a consistent safety profile, satralizumab's established use in NMOSD highlights a known risk of infections, including serious infections. Real-world data from NMOSD patients indicate that these risks may be higher in older individuals, those with longer disease duration, or patients on concomitant corticosteroids, necessitating careful patient selection and vigilant monitoring in the MOGAD population. Furthermore, while the 48-week data are robust, the long-term efficacy and safety of satralizumab specifically in MOGAD, particularly given the variable course of the disease (some patients may have a monophasic course or antibody disappearance), will require ongoing evaluation through post-marketing surveillance. The MOGAD treatment landscape, though currently lacking approved therapies, is not static; observational data for agents like rituximab and tocilizumab exist, and the urgent call for randomized controlled trials in MOGAD could lead to future competition, potentially challenging ENSPRYNG's market dominance over time. Ultimately, ENSPRYNG's potential approval for MOGAD represents a significant leap forward, but its successful integration into clinical practice will depend on balancing its clear benefits with a thorough understanding and management of its associated risks and the evolving competitive environment.